| Mrs Brooke Bucholtz Sperduto, LPC | |
|
250 Mathis Ferry Rd Ste 101, Mount Pleasant, SC 29464-2988 | |
| (843) 571-9171 | |
| (843) 971-5178 |
| Full Name | Mrs Brooke Bucholtz Sperduto |
|---|---|
| Gender | Female |
| Speciality | Counselor - Professional |
| Location | 250 Mathis Ferry Rd Ste 101, Mount Pleasant, South Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144568551 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YP2500X | Counselor - Professional | LPC 5457 (South Carolina) | Primary |
| 101YP2500X | Counselor - Professional | LPC006911 (Georgia) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Brooke Bucholtz Sperduto, LPC 250 Mathis Ferry Rd Ste 101, Mount Pleasant, SC 29464-2988 Ph: (843) 571-9171 | Mrs Brooke Bucholtz Sperduto, LPC 250 Mathis Ferry Rd Ste 101, Mount Pleasant, SC 29464-2988 Ph: (843) 571-9171 |
News Archive
Researchers at Yale School of Medicine and their colleagues at the Society for the Investigation of Early Pregnancy have helped clarify the function of a unique protein called Preimplantation Factor, which is produced by healthy embryos to direct embryo attachment and help the mother adapt to pregnancy.
International Medical News Group, LLC, an Elsevier company that provides medical news and information to physicians, announced today the launch of Cardiology Product Zone. This new product resource guide is launched in partnership with Pure Incubation, a company that specializes in developing data driven web properties and performance media programs that are focused exclusively on the product buying process.
Abbott and Reata Pharmaceuticals today announced that they have entered into a collaboration agreement to develop and commercialize bardoxolone methyl (bardoxolone), which is currently in late Phase 2 trials for the treatment of chronic kidney disease (CKD).
An international team of researchers has found that selpercatinib, a drug that precisely targets cancers driven by mutations or alterations in the gene RET, was effective at shrinking tumours in patients with nonsmall cell lung cancer (NSCLC), with a majority of patients living for more than a year without disease progression.
› Verified 6 days ago
Sandra Nelson, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 782 Johnnie Dodds Blvd Ste I, Mount Pleasant, SC 29464 Phone: 843-300-9105 Fax: 843-284-3931 | |
Steven Jesse Jahnke, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 871 Lowcountry Blvd Ste 200, Mount Pleasant, SC 29464 Phone: 843-501-1099 | |
Abigail Hankins, LPCA Counselor Medicare: Not Enrolled in Medicare Practice Location: 150 Heritage Cir, Mount Pleasant, SC 29464 Phone: 337-529-0074 | |
Lacey Atkins, LPCA Counselor Medicare: Not Enrolled in Medicare Practice Location: 222 W Coleman Blvd, Mount Pleasant, SC 29464 Phone: 843-405-2869 | |
Christina Arnoldi, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1514 Mathis Ferry Rd, Suite 212, Mount Pleasant, SC 29464 Phone: 843-732-2280 | |
Brittany Greene, M.ED., LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 268 W Coleman Blvd Ste A, Mount Pleasant, SC 29464 Phone: 843-936-2566 | |
Karen Lewis, LPCA Counselor Medicare: Not Enrolled in Medicare Practice Location: 207 Simmons St, Mount Pleasant, SC 29464 Phone: 843-714-5260 |